This paper considers the literature relating to the course of hepatitis C i
nfection and its implications for those with haemophilia. It goes on to dis
cuss a model that assessed the economic aspects of treating hepatitis C cas
es with interferon-alpha, discusses recent changes in recommended treatment
of hepatitis C and critically reviews the model and its application to pat
ients with haemophilia.